CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program

CalciMedica, Inc. has announced a definitive securities purchase agreement for a private placement financing valued at approximately $49 million, aimed at advancing its pulmonary hypertension strategy. The deal, disclosed on June 24, 2026, includes participation from both new and existing investors, including members of the company's Board of Directors and management team. The financing will support a Phase 1b proof-of-concept study evaluating Auxora™, CalciMedica's intravenous CRAC channel inhibitor, in patients with pulmonary arterial hypertension (PAH).

The private placement consists of 18,673,429 units, with each unit comprising one share of common stock or a pre-funded warrant, as well as rights to Series A and Series B warrants. The upfront gross proceeds from the placement are expected to be approximately $15 million, with additional potential proceeds from the exercise of warrants, which could bring the total to nearly $49 million if fully realized. This financing structure reflects a strategic approach to raising capital while providing investors with potential upside through warrant exercises.

CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies that inhibit calcium release-activated calcium (CRAC) channels, targeting serious inflammatory, immunologic, and cardiopulmonary diseases. The company aims to leverage its CRAC channel inhibition platform to address significant unmet needs in the pulmonary hypertension market, which is characterized by progressive right ventricular dysfunction and a lack of effective therapies. The anticipated data from the Phase 1b study is expected by mid-2027, coinciding with the expected IND clearance for CM5480, CalciMedica's proprietary oral CRAC channel inhibitor.

The strategic rationale behind this fundraising is underscored by the growing demand for innovative treatments in the pulmonary hypertension sector, which represents a multi-billion-dollar market. Current therapies primarily focus on the pulmonary vasculature, leaving a gap in treatments that also address right ventricular support and anti-remodeling activity. CalciMedica's approach, which has shown promise in preclinical models, aims to fill this gap and potentially revolutionize treatment options for patients suffering from PAH and other forms of pulmonary hypertension.

The successful completion of this financing could have broader implications for the biopharmaceutical sector, particularly in the development of novel therapies for chronic diseases. As investors continue to show confidence in innovative treatment strategies, companies like CalciMedica may pave the way for enhanced investment in the biopharmaceutical space. This trend could lead to increased competition and innovation, ultimately benefiting patients with serious health conditions and driving growth within the industry.